{"id":137519,"date":"2025-06-09T19:08:43","date_gmt":"2025-06-09T23:08:43","guid":{"rendered":"https:\/\/medcitynews.com\/?p=137519"},"modified":"2025-06-10T02:35:36","modified_gmt":"2025-06-10T06:35:36","slug":"merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/","title":{"rendered":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted"},"content":{"rendered":"

A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA approval<\/a>, introducing competition to products already available from Pfizer and Sanofi.<\/p>\n

The Monday regulatory decision for the antibody, known in development as clesrovimab, covers its use in newborns and infants entering their first RSV season, which spans the fall and winter months. For those born during RSV season, clesrovimab is to be administered soon after birth. Merck will market its new product under the brand name Enflonsia.<\/p>\n

RSV infection typically leads to symptoms resembling the common cold in healthy people. But in babies and older adults, the disease caused by RSV infection can lead to life-threatening breathing complications. For nearly three decades, the only FDA-approved product for protecting babies from the lower respiratory tract disease caused by RSV was Synagis, an antibody developed and commercialized by AstraZeneca. That product\u2019s approval covered its use only in premature babies. This antibody has a short half-life that requires monthly dosing. More recent advances in RSV research have led to products, such as Merck\u2019s Enflonsia, that require just a single injection.<\/p>\n

Enflonsia is an antibody designed to last in the body for about five months, which is long enough to protect an infant through a typical RSV season. The FDA decision for the product is based on results from a placebo-controlled Phase 2b\/3 clinical trial that enrolled 2,858 infants entering their first RSV season. Results showed a 60.5% reduction in the incidence of RSV-associated infections compared to placebo through five months. The antibody also led to a reduction in RSV-associated hospitalizations through five months. The most common adverse effect was injection site reactions. In a Phase 3 test that compared Enflonsia to Synagis, the safety of the Merck drug was comparable to the AstraZeneca product.<\/p>\n

Pfizer\u2019s presence in RSV is through Abrysvo, a vaccine comprised of an engineered version of RSV F protein antigen. It was first approved for use in older adults in 2023<\/a>. Later that year, the vaccine was approved for maternal immunization, in which immunization of a pregnant mother leads to the production of antibodies that are passed on to the baby. Last year, the FDA expanded Abrysvo\u2019s label to include adults age 18 to 59. Pfizer reported $755 million<\/a> in Abrysvo revenue in 2024 across all of its approved uses, down 15.1% from the prior year. The company attributed the decline to a significant reduction in U.S. vaccination rates for older adults, partly offset by strong demand for use of the product for maternal immunization.<\/p>\n

Sanofi\u2019s Beyfortus, approved in 2023<\/a>, has become the dominant product for infant protection from RSV. Similar to Merck\u2019s new RSV product, Beyfortus is a long-acting antibody that while technically a drug, is intended to protect like a vaccine. The antibody is designed with technology giving it a half-life that lasts about five months. Sanofi R&D executive Jon Heinrichs told MedCity News in 2023 that Beyfortus\u2019s advantage over maternal immunization<\/a> is that administration can be timed to offer the greatest protection during RSV season. By contrast, the timing of a birth can only be estimated, so antibodies produced from maternal immunization may no longer be effective by the time RSV season arrives or may wane during the season.<\/p>\n

Beyfortus is administered as a single intramuscular injection. Sanofi reported $1.6 billion in revenue for the product in 2024, more than double its sales in the prior year. Unlike Beyfortus, whose dosing depends on a patient\u2019s weight, Merck\u2019s Enflonsia is given as the same 105 mg dose regardless of patient weight. In a prepared statement, Dean Li, president of Merck Research Laboratories, said the company is committed to making Enflonsia available before the start of the upcoming RSV season.<\/p>\n

Recommendations for vaccine use come from the Centers for Disease Control and Prevention\u2019s Advisory Committee on Immunization Practices (ACIP). This committee is scheduled to convene June 25 to 27<\/a>. Merck said that it expects ACIP will discuss Enflonsia at this meeting.<\/p>\n

When the ACIP meeting happens, it will have an entirely new roster. The Department of Health and Human Services on Monday announced that the committee\u2019s 17 sitting members have been removed<\/a>. HHS said 13 of those members were appointed in 2024 under President Biden. All members will be replaced by new members currently under consideration. HHS Secretary Robert F. Kennedy Jr. said in the announcement that \u201ca clean sweep is necessary to reestablish public confidence in vaccine science.\u201d Kennedy went on to assert, without evidence, that the committee of independent advisors had been functioning \u201cas a rubber stamp for industry profit-taking agendas.\u201d<\/p>\n

The American Medical Association took issue with the dismissal of ACIP\u2019s members, stating that the committee has been trusted to provide science- and data-driven advice and guidance.<\/p>\n

\u201cPhysicians, parents, community leaders and public health officials rely on them for clinical guidance, public health information, and knowledge,\u201d Dr. Bruce Scott, president of the association, said in an emailed statement. \u201cToday\u2019s action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives. With an ongoing measles outbreak and routine child vaccination rates declining, this move will further fuel the spread of vaccine-preventable illnesses.\u201d<\/p>\n

[The following two paragraphs added with analyst comment.<\/em>] Leerink Partners analyst Daina Graybosch said the firing of ACIP\u2019s members increases risk to all vaccine manufacturers. The CDC typically adopts ACIP recommendations and under the Affordable Care Act, payers must cover ACIP-recommended vaccines without restriction or cost sharing. At best, the new committee members will need time to get up to speed, potentially delaying recommendations for less controversial products, such as Merck\u2019s Enflonsia, she said in a note sent to investors. At worst, the committee could upend current recommendations for existing vaccines. While the composition of the new committee is still to be determined, Graybosch said new members will likely be sympathetic to at least some of Kennedy\u2019s vaccine beliefs, such as the disproven link to autism.<\/p>\n

\u201cSince today\u2019s statement criticizes that the committee \u2018has never recommended against a vaccine,\u2019 it suggests that ACIP could be more critical of vaccines, which could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development,\u201d Graybosch said, referencing a comment Kennedy made in an opinion piece<\/a> published online Monday in the Wall Street Journal.<\/p>\n

Photo: Christopher Occhicone\/Bloomberg, via Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

FDA approval of Merck\u2019s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi\u2019s Beyfortus. The new Merck product is expected to be discussed by the CDC\u2019s Advisory Committee on Immunization Practices; ACIP will have an entirely new roster at its next meeting after all 17 sitting members were dismissed by Health and Human Services Secretary Robert F. Kennedy Jr. <\/p>\n","protected":false},"author":25932,"featured_media":14436,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,63,123,54],"tags":[52726,15507,12102,52725,6207,618,37681],"class_list":["post-137519","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-daily","category-legal","category-pharma-channel","tag-advisory-committee-on-immunization-practices","tag-cdc","tag-clinical-trials","tag-enflonsia","tag-fda","tag-merck","tag-respiratory-syncytial-virus"],"acf":[],"yoast_head":"\nMerck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News\" \/>\n<meta property=\"og:description\" content=\"FDA approval of Merck\u2019s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi\u2019s Beyfortus. The new Merck product is expected to be discussed by the CDC\u2019s Advisory Committee on Immunization Practices; ACIP will have an entirely new roster at its next meeting after all 17 sitting members were dismissed by Health and Human Services Secretary Robert F. Kennedy Jr.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-09T23:08:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-10T06:35:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"681\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted\",\"datePublished\":\"2025-06-09T23:08:43+00:00\",\"dateModified\":\"2025-06-10T06:35:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\"},\"wordCount\":1076,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg\",\"keywords\":[\"Advisory Committee on Immunization Practices\",\"cdc\",\"Clinical Trials\",\"Enflonsia\",\"FDA\",\"Merck\",\"respiratory syncytial virus\"],\"articleSection\":[\"BioPharma\",\"Daily\",\"Legal\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\",\"url\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\",\"name\":\"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg\",\"datePublished\":\"2025-06-09T23:08:43+00:00\",\"dateModified\":\"2025-06-10T06:35:36+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg\",\"width\":1024,\"height\":681},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News","og_description":"FDA approval of Merck\u2019s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi\u2019s Beyfortus. The new Merck product is expected to be discussed by the CDC\u2019s Advisory Committee on Immunization Practices; ACIP will have an entirely new roster at its next meeting after all 17 sitting members were dismissed by Health and Human Services Secretary Robert F. Kennedy Jr.","og_url":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/","og_site_name":"MedCity News","article_published_time":"2025-06-09T23:08:43+00:00","article_modified_time":"2025-06-10T06:35:36+00:00","og_image":[{"width":1024,"height":681,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted","datePublished":"2025-06-09T23:08:43+00:00","dateModified":"2025-06-10T06:35:36+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/"},"wordCount":1076,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg","keywords":["Advisory Committee on Immunization Practices","cdc","Clinical Trials","Enflonsia","FDA","Merck","respiratory syncytial virus"],"articleSection":["BioPharma","Daily","Legal","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/","url":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/","name":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg","datePublished":"2025-06-09T23:08:43+00:00","dateModified":"2025-06-10T06:35:36+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/03\/GettyImages-1230787969.jpg","width":1024,"height":681},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2025\/06\/merck-rsv-infants-enflonsia-fda-approval-mrk-acip-immunization-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/137519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=137519"}],"version-history":[{"count":0,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/137519\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/14436"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=137519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=137519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=137519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}